Rare Diseases Congress Market Analysis and Reports | Spain Conference Series

Market Analysis - Rare Diseases Congress 2020

Importance & Scope

There are more than 6000 Rare Diseases. Many rare diseases are diagnosed at the age of childhood, making diagnostic awareness and knowledge on treatment and care particularly important for pediatricians

The Rare Diseases are so rare that rarity can lead to several problems including: difficulties in obtaining timely, accurate diagnoses; lack of experienced healthcare supervisors; useful, reliable and timely information may be difficult to retrieve; research activities are very less; developing new pharmaceuticals may not be economically feasible; treatments are sometimes very expensive; and in developing countries, the problems are compounded by other resource limitations.

Rare Diseases Congress 2019 is emerging up with an exciting and high knowledge gaining conference program this year also which includes plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from throughout the world. We invite you to join us at the Rare Diseases and Orphan Drug Congress 2019 in Berlin where you will be sure to have a meaningful experience with scholars from around the world. The Rare Diseases Conference aims to extend the reach, impact and exchange of scholarly ideas through innovative technology, determined commitment and exceptional service. It aims to provide international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research on Rare iseases and Orphan Drugs.

Why Barcelona??

Berlin is the capital and the largest city of Germany, as well as one of its 16 constituent states. Berlin is the nation's capital and busiest city. It is mythological for its exceptional variability of attractions, its prosperous cultural scene and a way of life that's both fast-paced and relaxed. Berlin is a world city of ethos, politics, broadcasting and science. Its frugality is based on advanced firms and the provision sector, incorporating a diverse range of creative industries, research facilities, media corporations and convention venues. The metropolis is a popular tourist destination. Substantial industries also include information technology, medicines, biomedical engineering, clean tech, biotechnology, building and electronics. Berlin is home to world-prominent universities, orchestras, academies, and performing venues, and is host to many sporting events. 

Market Research Growth on Rare Diseases and Orphan Drugs

Nearly there are 7,000 different types of Rare Diseases and disorders it has estimated that 30 million people in the United States, 30 million in Europe and 350 million people over the globe suffer from Rare Diseases. Four by fifth of Rare Diseases are genetic in origin, among them affected individuals 50% of them will be children. The Rare Diseases are distributed in such a way that four fifth of the cases accounted by some 350 Rare Diseases. About only 5% of rare diseases are having approved drug treatment with only 326 new drugs being approved from the FDA and brought in to the market.

 

In 2018, Orphan Drug sales were of the order of 93 billion. Orphan Drugs represented 35% of the industry’s new drug approvals. The genetic diseases are subdivided by therapeutic area, which was leading the global market in the past will show similar traction in the coming next eight years. This segment is anticipated to be valued at US$ 56,241 by the end of 2025. According to Statistics of MRC, the Global Orphan Drug market is estimated at $145.89 million in 2018 and is expected to reach $265.63 million by 2022 growing at a CAGR of 10.5% from 2018 to 2022.

 

Major Associations Associated with Rare Diseases Research

Alzheimer's disease Organizations

Ann & Robert H. Lurie Children’s Hospital

Birmingham children’s Hospital

Boston Children’s Hospital

Canadian Organization for Rare Diseases

Chicago Rare Disease Foundation

Children’s hospital of Pittsburgh

Comer Children’s Hospital – University of Chicago

Cystic Fibrosis Foundation

European Union Committee of Experts on Rare Diseases

EURORDIS Rare Diseases Europe

EveryLife Foundation for Rare Diseases

Global Genes Allies in Rare Diseases

Guardian Hands Foundation

Hospitals Associated with Rare Diseases Research

IRDR Intractable & Rare Diseases Research

Japan Patient Association

Multiple Myeloma Research Foundation

National Alliances for Rare Diseases

National Institute of Health (NIH)

National Organization for Rare Diseases

NDC Medicine

Organization for Rare Diseases India (ORDI)

Orphan Europe

Philippine Society for Orphan Disorders

Rare Disease UK

Rare Diseases or Syndromes and Clinical Societies

Rare Diseases Foundation, Iran

Rare Diseases Patient Association Funding

Rare Diseases South Africa

Rare Diseases Translational Research Collaboration

Rare Disorders Society Singapore

RARE Foundation Alliance

Royal Society of Medicine

Short Bowel Syndrome Foundation

Students4RareDiseases

The Asia-Pacific Alliance of Rare Disease Organisations

The Boler-Parseghian Center for Rare & Neglected Diseases

The Boler-Parseghian Center for Rare & Neglected Diseases

The Children’s Hospital of Philadelphia

The Every Life Foundation for Rare Diseases

The Genetic and Rare Disorders Organization

The Greek Alliance for Rare Diseases

The Manton Center for Orphan Disease Research

U.S. Food and Drug Administration

UCLA Health

US hospital for Rare Disease Research

Major Universities Associated with Rare Diseases Research

Anahuac University North Campus, Mexico

Australian National University, Australia

Benha University, Egypt

Birmingham City University, UK

Center for Clinical Pharmacology, Belgium

Center for Rare Neurological Diseases, USA

Charles Darwin University Casoria Australia

Columbia University Medical Center, United States

Columbia University, USA

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Duke University, USA

Emory University, USA

GMEC, The Global Medical Excellence Cluster

Guangzhou Medical University, China

Harvard University, United States

Harvard University, USA

Imperial College London, United Kingdom

Infection Control University

Iqbal Chest Centre, Bangladesh

John Hopkins University, USA

Johns Hopkins University, United States

Karolinska University, Sweden

Kindai University, Japan

King Saud Bin Abdulaziz University, Saudi Arabia

King's College London, UK

Kumamoto University, Japan

Linnaeus University, Sweden

Macquarie University, Australia

Mayo Clinic College of Medicine, USA

McGill university   Montréal, Canada

McMaster University, Canada

Medi7 Bentleigh, Australia

Murdoch University   Murdoch, Australia

National Institutes of Health, USA

Newcastle University, Australia

Northwestern University, Qatar

Osaka University, Japan

Oxford University, UK

Philip Morris International R&D, Switzerland

Pompeu Fabra University, Spain

Queen Mary University, UK

Radboud University Medical Center, Netherlands

Rare Genomics Institute, USA

Research Institute of Hospital del Mar, Spain

Rizzoli Orthopedic Institute, Italy

Samsung Medical Center, South Korea

St George’s University of London, UK

St. George Hospital, Australia

Stanford University, USA

Tasmanian Health Service, Australia

The Chest & Heart Association of Bangladesh, Bangladesh

The Fourth Hospital of Harbin Medical University, China

The Jikei University School of Medicine, Japan

The Third Affiliated Hospital of Guangzhou Medical University, China

The University of Newcastle, Australia

Tufts university, United States

United Hospital, Bangladesh

University College London, UK

University of British Columbia, Canada

University of Buffalo, United States

University of California Los Angeles, United States

University of California, USA

University of Cambridge, USA

University of Canberra Bruce, Australia

University of Celiac Disease Center, USA

University of Chicago Medicine, USA

University of Colorado, USA

University of Groningen, Netherlands

University of Lincoln, UK

University of London Imperial College of Science Technology and Medicine, UK

University of Maastricht, Netherlands

University of Maryland Medical Center, Australia

University of Maryland Medical Center, United States

University of Melbourne, Australia

University of Minnesota, United States

University of Newcastle, Australia

University of Pennsylvania, USA

University of Pittsburgh Study

University of Pittsburgh, USA

University of Queensland, Australia

University of Tasmania, Australia

University of Toronto, Canada

University of Valencia, Spain

University of Washington, USA

University of Zurich, Switzerland

University-of-the-sunshine-coast, Australia

Weill Cornell Medical College, Qatar

Wits University, South Africa

Yale University School of Medicine, USA

Yonsei University, South Korea

Major Companies Associated with Rare Diseases and Orphan Drugs

700thespians Limited, UK

Abbott Laboratories, UK

Actavis, USA

Aegerion Pharmaceuticals, Japan

Alexion Pharmaceuticals Inc, Switzerland

Almirall, Spain

Amgen, USA

Amicus Therapeutics, USA

Amphastar Pharmaceuticals, Inc

Araim Pharmaceuticals

Astellas Pharma US

AstraZeneca, Switzerland

AstraZeneca, UK

Baxter International Deerfield

Bayer HealthCare, Germany

Bayer, Germany

Beacon Pharmaceuticals, Bangladesh

Biotie Therapies Corp, Finland

Bioxyne Limited, Australia

Boehringer Ingelheim, Germany

Celgene, Switzerland

Centrapharm Ltd, UK

Chiesi Pharmaceutical, Italy

Clalit Health Service, Israel

Cohero Health, USA

Daiichi Sankyo Europe, Germany

Daiichi Sankyo, Japan

Dohmen Life Science

Elma Reseach, UK

European Medicines Agency

Focus Scientific Research Center (FSRC), phamax, India

Forest Laboratories, USA

Gecko Health, USA

Generics (UK) Ltd, UK

Genus Oncology Vernon Hills, USA

Genzyme, USA

Gilead sciences, USA

GlaxoSmithKline, UK

Global Data, UK

Gsk, London

Hormosan Pharma, Germany

Hormosan Pharma, Germany

Ikris Pharma Network Pvt Ltd, India

Ikris Pharma Network Pvt Ltd, India

Kissei Pharmaceutical Co., Ltd, Japan

Kyowa Hakko Kirin Co. Ltd, Japan

Lallemand Pharma, Switzerland

Life Arc, UK

Marathon Pharmaceuticals

Merck & Co, USA

Millennium Pharmaceuticals

Napp Pharmaceuticals Ltd, UK

Novartis, Switzerland

NPS Pharmaceuticals

Octapharma, USA

Onyx Pharmaceuticals, USA

Otsuka Holdings Co., Ltd, Japan

Panmira Pharmaceuticals, LLC, USA

Pearl Therapeutics, Inc

Pfizer, USA

PharmaMar, USA

Prosensa, Netherlands

PT Boehringer Ingelheim, Indonesia

Queensland Respiratory Laboratory Pty. Ltd, Australia

Ranbaxy Laboratories Limited

Raptor Therapeutics

Roche, Switzerland

Samsung Medical Center, South Korea

Sanofi, France

Sarepta Therapeutics, USA

Sigma-Tau Pharmaceuticals, Italy

Sunovion Pharmaceuticals, USA

Swedish Orphan Biovitrum AB, Sweden

Takeda, Japan

TriStem Corp Ltd, UK

Vertex Pharmaceuticals, USA

ViroPharma

ViroPharma, USA

Visionary Pharmaceuticals, Inc, USA

Yungjin Pharm Ind. Co., Ltd, South Korea

Summary

Rare Diseases are that affects a small percentage of the population all over the world. An Orphan Disease is Rare Diseases with a lack of a market large enough to gain support and sources for discovering treatments for it, with advances to research in orphan diseases advantageous conditions to creating and selling such treatments. Rare diseases are genetic and are present throughout the entire life of individual suffering, even if symptoms do not immediately appear. Many Rare Diseases seems to appear early in life, and about 30% of children affecting with rare pediatric diseases will die before getting 5 year old. Rare Diseases are generally genetic and so they chronic. It is estimates that at least 80% of them have identified genetic origins. Other Rare Diseases are the result of infections and allergies or it may be due to degenerative and proliferative causes and discovering the well-advanced treatments in Rare Diseases and Orphan Drugs.